Skip to main content
TipRanks
Go Ultimate75% OFF

Mochida Pharmaceutical Co., Ltd. (MFY) AI Stock Analysis

1 Followers
DE:MFY

Mochida Pharmaceutical Co., Ltd.

(Frankfurt:MFY)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Conservative Balance SheetMochida’s conservative balance sheet provides financial flexibility to sustain research, product development, and commercial operations. Low historical leverage also reduces financing pressure and improves resilience if earnings weaken or the pharmaceutical environment becomes less favorable.
Negative Factors
Unstable Cash ConversionVolatile cash generation makes reported earnings less dependable as a source of internally funded investment. Repeated negative operating and free cash flow can constrain flexibility, increase reliance on balance-sheet resources, and complicate planning for development and commercial priorities.

Mochida Pharmaceutical Co., Ltd. (MFY) vs. iShares MSCI Germany ETF (EWG)

-10%-5%0%5%10%15%20%25%DE:MFY+8.83%EWG+7.58%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 654.19M
Dividend Yield
2.38%
Average Volume (3M)
―
Price to Earnings (P/E)
11.1
Beta (1Y)
0.49
Revenue Growth
4.45%
EPS Growth
45.35%
Country
Germany
Employees
1,479
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Mochida Pharmaceutical Co., Ltd. Business Overview & Revenue Model

Company Description

Established in 1913 and headquartered in Tokyo, Japan, Mochida Pharmaceutical Co., Ltd. specializes in the development, manufacturing, and distribution of a wide array of medical and personal care products. Its primary offerings encompass pharmaceuti...

Mochida Pharmaceutical Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:MFY against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:4547JP:454773OutperformJPY 179.73B16.324.95%4.66%5.87%-21.16%
JP:4569JP:456958NeutralJPY 58.75B165.09―4.21%-6.48%-95.83%
JP:4887JP:488756NeutralJPY 168.09B19.38―3.32%2.43%―
JP:4521JP:452153NeutralJPY 138.31B15.896.11%4.95%5.43%1167.62%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
JP:4553JP:455350NeutralJPY 166.84B42.772.10%2.36%7.06%-81.10%

* Healthcare Sector Average

Performance Comparison

-20%0%20%40%DE:MFYJP:4521JP:4547JP:4553JP:4569JP:4887Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:MFY and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:MFYMochida Pharmaceutical Co., Ltd.18.901.9211.34%
JP:4521Kaken Pharmaceutical Co 3840.00334.249.53%
JP:4547Kissei Pharmaceutical Co 4400.00341.988.43%
JP:4553Towa Pharmaceutical Co 3390.00461.5415.76%
JP:4569KYORIN Pharmaceutical Co.,Ltd.1116.00-258.56-18.81%
JP:4887SAWAI GROUP HOLDINGS Co., Ltd.1686.50-141.66-7.75%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.